Targeting inflammatory pathway reduces Alzheimer's disease in mice

Alzheimer's disease (AD) is the most common form of dementia and is characterized by the formation of β-amyloid plaques throughout the brain. Proteins known as chemokines regulate inflammation and the immune response. In both patients with AD and mouse AD models, the chemokine CXCL10 is found in high concentrations in the brain and may contribute to AD. A new study in the Journal of Clinical Investigation indicates that activation of the CXCL10 receptor, CXCR3, contributes to AD pathology. Using a murine model of AD, Michael Heneka and colleagues at the University of Bonn found that mice lacking CXCR3 had reduced β-amyloid plaque formation. Importantly, loss of CXCR3 signaling in AD mice attenuated behavioral deficits. The results of this study suggest that CXCR3 should be explored as a potential therapeutic target for AD.

###

TITLE: CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer's disease model

AUTHOR CONTACT: Michael Heneka
University of Bonn, Bonn, UNK, DEU
Phone: +49 228 28713092; E-mail: [email protected]

View this article at: http://www.jci.org/articles/view/66771?key=33c646960796f7d970df

Contact: Corinne Williams
[email protected]
Journal of Clinical Investigation
@jclinicalinvest

Suggested Articles

German scientists are targeting a protein-cutting enzyme that many viruses, including the coronavirus COVID-19, need to replicate.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.